MediWound (NASDAQ:MDWD) Stock Crosses Below 200 Day Moving Average – Time to Sell?

MediWound Ltd. (NASDAQ:MDWD)’s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $16.11 and traded as low as $14.17. MediWound shares last traded at $14.19, with a volume of 65,589 shares changing hands.

Analysts Set New Price Targets

MDWD has been the subject of a number of research reports. Oppenheimer reiterated an “outperform” rating and set a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, MediWound currently has a consensus rating of “Hold” and an average price target of $34.00.

MediWound Trading Up 0.8%

The firm’s 50 day simple moving average is $14.37 and its 200-day simple moving average is $16.09. The stock has a market capitalization of $184.91 million, a price-to-earnings ratio of -6.37 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same period in the prior year, the business posted ($0.07) EPS. As a group, equities research analysts predict that MediWound Ltd. will post -2.31 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David Morton Fox purchased 3,537 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was purchased at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the purchase, the director directly owned 22,283 shares in the company, valued at $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On MediWound

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers lifted its stake in MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 481 shares during the last quarter. Russell Investments Group Ltd. increased its position in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the last quarter. BNP Paribas Financial Markets increased its position in MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the period. Finally, Quarry LP bought a new stake in MediWound in the fourth quarter valued at approximately $26,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.